Thetis Pharmaceuticals

Thetis Pharmaceuticals is pioneering a novel therapeutic approach by developing TP-317, a stable, oral small molecule agonist of the BLT1 receptor based on the endogenous pro-resolving lipid mediator Resolvin E1 (RvE1). The company is targeting significant unmet needs in inflammatory bowel disease (IBD) and oncology, with a Phase 1a study in healthy volunteers completed and a Phase 1b study in ulcerative colitis patients planned for late 2026. Led by an experienced management team with deep expertise in pharmaceutical development and resolution biology, Thetis is a private, pre-revenue company advancing a platform that aims to restore tissue and immune homeostasis rather than broadly suppressing inflammation.

Platform for stabilizing and orally delivering Resolvin E1 (RvE1), a specialized pro-resolving lipid mediator, to activate the BLT1 receptor and promote tissue and immune homeostasis.

In IBD, Thetis competes against entrenched biologics (anti-TNF, anti-integrin, anti-IL) and newer oral JAK/S1P inhibitors. Its differentiation is a potentially superior safety profile and direct healing effect. In oncology, it would compete with a vast array of immuno-oncology agents, aiming to enhance their efficacy by resolving the pro-tumor inflammatory microenvironment.